We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00749099
Recruitment Status : Terminated (No longer required study by FDA for NDA approval.)
First Posted : September 9, 2008
Last Update Posted : February 22, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
The overall purpose of this research is to demonstrate (or measure) the intestinal availability of lipase, amylase, and protease (enzymes the body has a shortage of) from PANCRECARB® when administered with a meal.

Condition or disease Intervention/treatment
Exocrine Pancreatic Insufficiency Drug: pancrelipase Drug: placebo

Detailed Description:
Eligible patients for this placebo-controlled study had confirmed exocrine pancreatic insufficiency with a stool pancreatic elastase of <75 mcg/g. Patients who satisfied all inclusion criteria are prepared for endoscopic placement of three Liguory nasal biliary aspiration catheters: one 8.5 fr. catheter in the distal duodenum for aspiration, one 7.0 fr. catheter in the first portion of the duodenum for infusion of a PEG marker (4 mL/min) and one 7.0 fr. in the stomach for aspiration. Baseline samples are obtained from the gastric and distal duodenal ports and placed on ice. Subjects are then asked to swallow 5 capsules of a placebo (Phase I) or the test drug (PANCRECARB® (pancrelipase) - Phase II) with a standardized Lundh meal. Gastric samples are collected once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each). All collected samples were tested for the following parameters to demonstrate bioavailability of enzymes originating from PANCRECARB® (pancrelipase): lipase, amylase and protease activities, pH (bicarbonate), and protein fingerprinting by SDS-PAGE analysis.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: 092206: Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum) From PANCRECARB® (Pancrelipase), Delayed Release Capsules, Buffered and Enteric-Coated Microspheres
Study Start Date : April 2007
Primary Completion Date : September 2010
Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: Phase I
All subject participate in Phase I
Drug: placebo

5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.

Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).

Active Comparator: Phase II
All subject participate in Phase II
Drug: pancrelipase

The test drug (PANCRECARB® [pancrelipase] - Phase II) with a standardized Lundh meal.

Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).


Outcome Measures

Primary Outcome Measures :
  1. Evidence of the bioavailability of lipase, amylase and protease in the upper intestine from exogenously administered PANCRECARB® (pancrelipase), when taken with a Lundh test meal. [ Time Frame: 4 hours post administration of PANCRECARB® and or Placebo ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented chronic pancreatitis, alcohol induced chronic pancreatitis or cystic fibrosis
  • Documented pancreatic enzyme insufficiency as determined by spot fecal elastase-1 <75 mcg/g stool at the time of inclusion in the study
  • Required daily exogenous enzyme supplementation with commercially available pancreatic enzymes
  • > 18 years of age
  • Male and female subjects qualify
  • Able to swallow capsules
  • Clinically stable with no evidence of an acute medical condition
  • History of steatorrhea

Exclusion Criteria:

  • History of fibrosing colonopathy in CF subjects
  • Current diagnosis or a history of distal intestinal obstruction syndrome (DIOS) in the past 4 months
  • Known contraindication, sensitivity or hypersensitivity to porcine pancreatic enzymes
  • Active liver disease
  • ALT or AST >3 times the upper limit of normal
  • Bilirubin >3 times the upper limit of normal
  • Acute pancreatitis or acute exacerbation of chronic pancreatitis
  • Acute treatment with any systemic (oral or IV) antibiotics two weeks prior to screening
  • Subjects on erythromycin unwilling to discontinue the treatment two weeks prior to screening
  • Receiving treatment with antacids or H2 receptor blockers or proton pump inhibitors and unable to discontinue these treatments prior to day 1
  • Inability to cooperate with or non-compliant with required study procedures
  • Pregnant, breast feeding
  • Current daily prescribed scheduled use of narcotics (patients requiring PRN use of narcotics are not excluded)
  • Poorly controlled diabetes
  • A medical condition which the investigator deems significant enough to interfere with the ability of the subject to participate in the intubation study or interfering with assessment or enzyme bioavailability
  • Stomach pH > 4
  • Small bowel disease (i.e. celiac disease)
More Information

Responsible Party: Digestive Care, Inc.
ClinicalTrials.gov Identifier: NCT00749099     History of Changes
Other Study ID Numbers: DCI092206
IRB #14687
First Posted: September 9, 2008    Key Record Dates
Last Update Posted: February 22, 2013
Last Verified: February 2013

Additional relevant MeSH terms:
Exocrine Pancreatic Insufficiency
Pancreatic Diseases
Digestive System Diseases
Gastrointestinal Agents